Table 3.
Secondary outcomes between baseline and 12 months.
| Baseline | 3 months | 6 months | 12 months | p value | |
|---|---|---|---|---|---|
| Radiopaque pellets test (number of radiopaque pellets on day 7) | |||||
| Donor FMT | 20.6 (2.0) | 22.1 (2.1) | 19.2 (2.1) | 19.4 (2.1) | 0.0252 |
| Placebo FMT | 18.6 (2.1) | 19.4 (2.1) | 23.7 (2.1) | 25.5 (2.2) | |
| Levodopa-equivalent daily dose (mg) | |||||
| Donor FMT | 383.0 (53.3) | 398.8 (57.2) | 399.5 (57.0) | 429.1 (59.0) | 0.8350 |
| Placebo FMT | 431.1 (50.8) | 429.7 (54.7) | 442.1 (54.5) | 455.9 (56.5) | |
| Non-Motor Symptoms Scale for Parkinson's Disease (NMSS) | |||||
| Donor FMT | 45.8 (9.1) | 50.1 (8.9) | 48.2 (8.6) | 54.7 (8.3) | 0.1443 |
| Placebo FMT | 44.4 (8.6) | 31.6 (8.5) | 35.9 (8.3) | 33.4 (8.0) | |
| Parkinson's Disease Quality of Life Questionnaire (PDQ-39) | |||||
| Donor FMT | 34.4 (4.7) | 32.8 (4.5) | 35.4 (4.8) | 36.5 (4.6) | 0.5439 |
| Placebo FMT | 26.2 (4.4) | 24.3 (4.3) | 26.8 (4.6) | 25.0 (4.5) | |
| Wexner Constipation Scale | |||||
| Donor FMT | 6.7 (1.3) | 6.8 (1.0) | 6.7 (1.0) | 6.7 (1.1) | 0.7696 |
| Placebo FMT | 5.8 (1.2) | 5.5 (1.0) | 4.7 (1.0) | 5.1 (1.0) | |
| Geriatric Depression Scale (GDS) | |||||
| Donor FMT | 17.5 (0.7) | 17.2 (0.6) | 17.4 (0.6) | 16.8 (0.6) | 0.1674 |
| Placebo FMT | 17.3 (0.6) | 17.3 (0.6) | 17.7 (0.5) | 18.3 (0.6) | |
| Parkinson Anxiety Scale (PAS) | |||||
| Donor FMT | 8.7 (1.8) | 9.7 (1.7) | 8.1 (1.7) | 9.6 (1.7) | 0.1519 |
| Placebo FMT | 8.8 (1.7) | 8.0 (1.6) | 8.2 (1.6) | 8.2 (1.6) | |
| Lille Apathy Rating Scale (LARS) | |||||
| Donor FMT | −19.4 (1.5) | −19.8 (1.6) | −19.0 (1.5) | −19.3 (1.4) | 0.4253 |
| Placebo FMT | −20.7 (1.4) | −21.2 (1.5) | −21.9 (1.5) | −22.4 (1.3) | |
| Parkinson's Disease Sleep Scale (PDSS) | |||||
| Donor FMT | 101.1 (5.7) | 104.5 (5.5) | 101.3 (5.4) | 102.7 (5.3) | 0.7290 |
| Placebo FMT | 109.7 (5.4) | 109.7 (5.3) | 108.8 (5.3) | 110.5 (5.1) | |
| Parkinson's Fatigue Scale (PFS) | |||||
| Donor FMT | 37.3 (3.2) | 39.6 (2.9) | 40.0 (3.1) | 43.4 (3.2) | 0.0418 |
| Placebo FMT | 34.7 (3.0) | 35.7 (2.8) | 34.7 (3.0) | 33.4 (3.2) | |
| Montreal Cognitive Assessment (MoCA) | |||||
| Donor FMT | 27.6 (0.3) | – | 28.4 (0.3) | 28.2 (0.2) | 0.4828 |
| Placebo FMT | 28.2 (0.3) | – | 28.7 (0.3) | 28.9 (0.2) | |
Data are mean (SEM). MDS-UPDRS, Movement Disorders Society Unified Parkinson's Disease Rating Scale. Significant differences (p < 0.05) are indicated in bold.